SLC5A2 and myocardial infarction: In clinical practice, while SGLT2 inhibitors are used in patients for blood glucose management, heart failure, and chronic kidney disease, they are not recommended for use as secondary prevention of future myocardial infarction to reduce ischemia–reperfusion injury.